- Home
- PDD vs VRTX Comparison
PDD vs VRTX Comparison
Compare PDD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDD
- VRTX
- Stock Information
- Founded
- PDD 2015
- VRTX 1989
- Country
- PDD Ireland
- VRTX United States
- Employees
- PDD N/A
- VRTX N/A
- Industry
- PDD Business Services
- VRTX EDP Services
- Sector
- PDD Consumer Discretionary
- VRTX Technology
- Exchange
- PDD Nasdaq
- VRTX Nasdaq
- Market Cap
- PDD 139.0B
- VRTX 119.6B
- IPO Year
- PDD 2018
- VRTX 1991
- Fundamental
- Price
- PDD $98.94
- VRTX $397.27
- Analyst Decision
- PDD Strong Buy
- VRTX Buy
- Analyst Count
- PDD 10
- VRTX 30
- Target Price
- PDD $173.40
- VRTX $513.68
- AVG Volume (30 Days)
- PDD 11.3M
- VRTX 1.8M
- Earning Date
- PDD 11-21-2024
- VRTX 02-03-2025
- Dividend Yield
- PDD N/A
- VRTX N/A
- EPS Growth
- PDD 133.06
- VRTX N/A
- EPS
- PDD 10.49
- VRTX N/A
- Revenue
- PDD $53,048,260,958.00
- VRTX $10,625,800,000.00
- Revenue This Year
- PDD $62.39
- VRTX $12.54
- Revenue Next Year
- PDD $24.98
- VRTX $8.52
- P/E Ratio
- PDD $9.48
- VRTX N/A
- Revenue Growth
- PDD 87.39
- VRTX 10.06
- 52 Week Low
- PDD $88.01
- VRTX $377.85
- 52 Week High
- PDD $164.69
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- PDD 39.62
- VRTX 24.08
- Support Level
- PDD $99.60
- VRTX $377.85
- Resistance Level
- PDD $103.66
- VRTX $474.19
- Average True Range (ATR)
- PDD 2.84
- VRTX 12.72
- MACD
- PDD 0.56
- VRTX -6.53
- Stochastic Oscillator
- PDD 13.37
- VRTX 19.69
About PDD PDD Holdings Inc.
PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. PDD aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from the increased productivity and new opportunities. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.